logo

For the Inventor, By the Inventor

Mobara, Japan

Tetsuya Nagata

This inventor holds 109 USPTO granted patents and 27 published patent applications and 6 EPO patents, primarily in Nucleic Acid Technologies (CPC class C12N15-113). Top assignees: Nec Corporation, Hitachi, Ltd., National Center of Neurology and Psychiatry. Active years: 1988-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tetsuya Nagata. Retrieved from https://idiyas.com/inventor/tetsuya-nagata

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 109 

% Patents Active = 88.1

 

Average Co-Inventor Count = 3.3

ph-index = 20

Forward Citations = 1,166(Granted Patents)

Forward Citations (Not Self Cited) = 1,092(Dec 10, 2025)


Inventors with similar research interests:

🔬 See more inventors

Location History:

  • Hitachi, JP (1988 - 1998)
  • Katsuta, JP (1995 - 2005)
  • Ibaraki, JP (2001 - 2007)
  • Hadano, JP (2008)
  • Hitachinaka, JP (1999 - 2012)
  • Chiba, JP (2006 - 2014)
  • Kawasaki, JP (2015)
  • Ota-ku, JP (2015)
  • Nakahara-ku, JP (2018)
  • Mobara, JP (2003 - 2020)
  • Kodaira, JP (2017 - 2021)
  • Minato-ku, JP (2021)
  • Tokyo, JP (1991 - 2024)

Company Filing History:

goldMedal23 out of 36,684 
 
Nec Corporation
 patents
silverMedal21 out of 42,731 
 
Hitachi, Ltd.
 patents
bronzeMedal19 out of 43 
 
National Center of Neurology and Psychiatry
 patents
4. 19 out of 229 
 
Nippon Shinyaku Company, Ltd.
 patents
5. 16 out of 1,207 
 
Hitachi Displays, Ltd.
 patents
6. 16 out of 5,795 
 
Japan Display Inc.
 patents
7. 13 out of 1,238 
 
Panasonic Liquid Crystal Display Co., Ltd.
 patents
8. 5 out of 135 
 
Tokyo Medical and Dental University
 patents
9. 3 out of 23 
 
Hitachi Process Computer Engineering, Inc.
 patents
10. 3 out of 426 
 
Nec Display Solutions, Ltd.
 patents
11. 2 out of 1,267 
 
Hitachi Koki Co., Ltd.
 patents
12. 2 out of 2,903 
 
Seiko Instruments Inc
 patents
13. 1 out of 217 
 
Hitachi Device Engineering Co., Ltd.
 patents
14. 1 out of 360 
 
Keio University
 patents
15. 1 out of 1,226 
 
Takeda Pharmaceutical Company Limited
 patents
16. 3 out of 834,513 
Other
 patents
where one patent can have more than one assignee

Years Active: 1988-2026

Loading Chart...
Loading Chart...
Areas of Expertise:
Antisense Nucleic Acids
Blood-Brain Barrier
Nucleic Acid Complex
Liquid Crystal Display
Organic Electroluminescent Device
Flexible Display
Data Communication
Display Device
109 patents (USPTO):Explore Patents
1. 12746253 - BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID (2026-09-29),
2. 12305169 - BBB-crossing lipid ligand of hetero nucleic acid (2025-05-20),
3. 12060556 - Antisense nucleic acids (2024-08-13),
4. 11851654 - Nucleic acid with reduced toxicity (2023-12-26),
5. 11597928 - Nucleic acid complex (2023-03-07),
6. 11433089 - Blood-brain barrier permeable heteroduplex nucleic acid (2022-09-06),
7. 11193125 - Antisense nucleic acids (2021-12-07),
8. 11053497 - Antisense nucleic acids (2021-07-06),
9. 11028122 - Antisense nucleic acids (2021-06-08),
10. 10916597 - Display device (2021-02-09),
11. 10870676 - Antisense nucleic acids (2020-12-22),
12. 10845651 - Liquid crystal display device (2020-11-24),
13. 10781448 - Antisense nucleic acids (2020-09-22),
14. 10683322 - Antisense nucleic acids (2020-06-16),
15. 10662217 - Antisense nucleic acids (2020-05-26),

Title: Tetsuya Nagata - Innovator in Nucleic Acid Therapeutics

Introduction

Tetsuya Nagata, based in Mobara, Japan, is a prominent inventor known for his significant contributions to the field of nucleic acid therapeutics. With an impressive portfolio of 107 patents, Nagata has been a driving force in the development of innovative therapies aimed at improving healthcare outcomes.

Latest Patents

Nagata's latest inventions focus on advancing the efficacy and safety of antisense nucleic acids. One of his notable patents is the development of a drug that enables highly-efficient skipping of exons, involving an antisense oligomer that connects multiple unit oligomers targeting sequences in the same exon without overlap. Additionally, he has developed a low toxicity antisense nucleic acid medicine designed to modulate the expression of target transcriptional products, particularly in the central nervous system. This innovation involves a nucleic acid complex formed by annealing a first nucleic acid strand with an antisense oligonucleotide region to a second complementary strand.

Career Highlights

Tetsuya Nagata has garnered extensive experience throughout his career, having worked with prestigious companies such as NEC Corporation and Hitachi, Ltd. His expertise in nucleic acid technology has been pivotal in pioneering novel therapeutic strategies that address critical healthcare challenges.

Collaborations

During his career, Nagata has collaborated with notable colleagues, including Shin'ichi Takeda and Naoki Watanabe. These collaborations have fostered a creative environment that has facilitated the advancement of groundbreaking innovations in the field of genetic medicine.

Conclusion

Tetsuya Nagata's contributions to the realm of nucleic acid therapeutics underscore his commitment to innovation in healthcare. With a remarkable patent portfolio and a history of influential collaborations, Nagata continues to inspire future generations of inventors and researchers in the pursuit of effective medical solutions. His work exemplifies the intersection of science and innovation in addressing complex health issues.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…